◎ Sugi Atlas

Atlas / Drug / Telisotuzumab Vedotin

Telisotuzumab Vedotin

drug
On this page

Also known as Abbv 399ABBV-399ABT-399PR-1420682Telisotuzumab vedotinaTelisotuzumab vedotine

Summary

Telisotuzumab Vedotin (CHEMBL3990032) is a phase-3 clinical-stage antibody drug conjugate targeting MET; indicated across 3 conditions including non-small cell lung carcinoma and squamous cell lung carcinoma.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Antibody drug conjugate
  • Targets: 1 (MET)
  • Indications: 3 conditions
  • Clinical trials: 10

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL3990032
NameTelisotuzumab Vedotin
TypeAntibody drug conjugate
Max phase3

Also known as: Abbv 399, ABBV-399, ABT-399, PR-1420682, Telisotuzumab vedotin, Telisotuzumab vedotina, Telisotuzumab vedotine, TELISOTUZUMAB VEDOTIN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
METMET proto-oncogene, receptor tyrosine kinaseBinding9.662.4%P08581

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): MET.

Top Reactome pathways

44 total, by targets touching each:

PathwayTargetsGenes
PIP3 activates AKT signaling1MET
Developmental Biology1MET
Signal Transduction1MET
Disease1MET
Negative regulation of the PI3K/AKT network1MET
Generic Transcription Pathway1MET
PI3K/AKT Signaling in Cancer1MET
Constitutive Signaling by Aberrant PI3K in Cancer1MET
Semaphorin interactions1MET
Sema4D in semaphorin signaling1MET
Sema4D mediated inhibition of cell attachment and migration1MET
Axon guidance1MET
Diseases of signal transduction by growth factor receptors and second messengers1MET
Infectious disease1MET
RAF/MAP kinase cascade1MET
MAPK family signaling cascades1MET
MAPK1/MAPK3 signaling1MET
Signaling by MET1MET
MET Receptor Activation1MET
Negative regulation of MET activity1MET
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling1MET
RNA Polymerase II Transcription1MET
Gene expression (Transcription)1MET
MET activates RAS signaling1MET
MET activates PI3K/AKT signaling1MET
MET activates PTPN111MET
MET activates PTK2 signaling1MET
InlB-mediated entry of Listeria monocytogenes into host cell1MET
MET interacts with TNS proteins1MET
MET activates RAP1 and RAC11MET
MET receptor recycling1MET
MET activates STAT31MET
MET promotes cell motility1MET
Listeria monocytogenes entry into host cells1MET
Transcriptional Regulation by MECP21MET
Intracellular signaling by second messengers1MET
Signaling by Receptor Tyrosine Kinases1MET
MECP2 regulates neuronal receptors and channels1MET
Nervous system development1MET
MITF-M-regulated melanocyte development1MET
Drug-mediated inhibition of MET activation1MET
Bacterial Infection Pathways1MET
Regulation of MITF-M-dependent genes involved in cell cycle and proliferation1MET
MITF-M-dependent gene expression1MET

Dominant GO biological processes

GO termTargets
endothelial cell morphogenesis1
liver development1
cell surface receptor signaling pathway1
cell surface receptor protein tyrosine kinase signaling pathway1
negative regulation of autophagy1
neuron differentiation1
pancreas development1
positive regulation of transcription by RNA polymerase II1
hepatocyte growth factor receptor signaling pathway1
branching morphogenesis of an epithelial tube1
positive chemotaxis1
excitatory postsynaptic potential1
semaphorin-plexin signaling pathway1
negative regulation of hydrogen peroxide-mediated programmed cell death1
positive regulation of endothelial cell chemotaxis1

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
squamous cell lung carcinoma2MONDO:0005097EFO:0000708
neoplasm1MONDO:0005070MONDO:0004992

Clinical trials

Total trials: 10.

Phase distribution

PhaseTrials
PHASE25
PHASE32
PHASE12
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04928846PHASE3RECRUITINGA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06093503PHASE3WITHDRAWNStudy of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
NCT03539536PHASE2ACTIVE_NOT_RECRUITINGStudy of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT06568939PHASE2RECRUITINGA Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT07323641PHASE2RECRUITINGTelisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
NCT03574753PHASE2COMPLETEDLung-MAP S1400K: c-MET Positive
NCT05513703PHASE2TERMINATEDA Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02099058PHASE1ACTIVE_NOT_RECRUITINGA Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
NCT03311477PHASE1COMPLETEDA Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors
NCT04830202Not specifiedTEMPORARILY_NOT_AVAILABLEExpanded Access to Telisotuzumab Vedotin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

84 molecules share ≥1 primary target. Top 84 by shared-target count:

MoleculeSourceStatusShared targets
AFATINIBChEMBL + PubChemPhase 4 (approved)MET
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)MET
PAZOPANIBChEMBL + PubChemPhase 4 (approved)MET
AFATINIB DIMALEATEChEMBLPhase 4 (approved)MET
AXITINIBChEMBLPhase 4 (approved)MET
BOSUTINIBChEMBLPhase 4 (approved)MET
BRIGATINIBChEMBLPhase 4 (approved)MET
CABOZANTINIBChEMBLPhase 4 (approved)MET
CABOZANTINIB S-MALATEChEMBLPhase 4 (approved)MET
CAPMATINIBChEMBLPhase 4 (approved)MET
CERITINIBChEMBLPhase 4 (approved)MET
DABRAFENIBChEMBLPhase 4 (approved)MET
ENSARTINIBChEMBLPhase 4 (approved)MET
ENTRECTINIBChEMBLPhase 4 (approved)MET
ERLOTINIBChEMBLPhase 4 (approved)MET
FEDRATINIBChEMBLPhase 4 (approved)MET
GEFITINIBChEMBLPhase 4 (approved)MET
INFIGRATINIBChEMBLPhase 4 (approved)MET
MIDOSTAURINChEMBLPhase 4 (approved)MET
NERATINIBChEMBLPhase 4 (approved)MET
NINTEDANIBChEMBLPhase 4 (approved)MET
PALBOCICLIBChEMBLPhase 4 (approved)MET
SORAFENIBChEMBLPhase 4 (approved)MET
SUNITINIBChEMBLPhase 4 (approved)MET
TEPOTINIBChEMBLPhase 4 (approved)MET
TIVOZANIBChEMBLPhase 4 (approved)MET
VANDETANIBChEMBLPhase 4 (approved)MET
CANERTINIBChEMBLPhase 3MET
CEDIRANIBChEMBLPhase 3MET
DACTOLISIBChEMBLPhase 3MET
ENZASTAURINChEMBLPhase 3MET
EPIGALOCATECHIN GALLATEChEMBLPhase 3MET
LESTAURTINIBChEMBLPhase 3MET
LINIFANIBChEMBLPhase 3MET
LINSITINIBChEMBLPhase 3MET
POZIOTINIBChEMBLPhase 3MET
QUERCETINChEMBLPhase 3MET
RIGOSERTIBChEMBLPhase 3MET
SAVOLITINIBChEMBLPhase 3MET
SITRAVATINIBChEMBLPhase 3MET
TIVANTINIBChEMBLPhase 3MET
ALTIRATINIBChEMBLPhase 2MET
AMG-208ChEMBLPhase 2MET
AMG-337ChEMBLPhase 2MET
AT-9283ChEMBLPhase 2MET
BEMCENTINIBChEMBLPhase 2MET
BI-2536ChEMBLPhase 2MET
BMS-754807ChEMBLPhase 2MET
BMS-777607ChEMBLPhase 2MET
CENISERTIBChEMBLPhase 2MET
CEP-32496ChEMBLPhase 2MET
DALMELITINIBChEMBLPhase 2MET
DECERNOTINIBChEMBLPhase 2MET
DEFOSBARASERTIBChEMBLPhase 2MET
ELLAGIC ACIDChEMBLPhase 2MET
ELZOVANTINIBChEMBLPhase 2MET
ENVONALKIBChEMBLPhase 2MET
FORETINIBChEMBLPhase 2MET
GLESATINIBChEMBLPhase 2MET
GOLVATINIBChEMBLPhase 2MET
GUMARONTINIBChEMBLPhase 2MET
ILORASERTIBChEMBLPhase 2MET
MERESTINIBChEMBLPhase 2MET
MK-2461ChEMBLPhase 2MET
NINGETINIBChEMBLPhase 2MET
OSI-632ChEMBLPhase 2MET
PELITINIBChEMBLPhase 2MET
R-406ChEMBLPhase 2MET
RAF-265ChEMBLPhase 2MET
RAVOXERTINIBChEMBLPhase 2MET
REBASTINIBChEMBLPhase 2MET
SAR-125844ChEMBLPhase 2MET
SU-014813ChEMBLPhase 2MET
TOZASERTIBChEMBLPhase 2MET
UCN-01ChEMBLPhase 2MET
VABAMETKIBChEMBLPhase 2MET
VEBRELTINIBChEMBLPhase 2MET
BinimetinibPubChemApprovedMET
dacomitinibPubChemApprovedMET
FostamatinibPubChemApprovedMET
IdelalisibPubChemApprovedMET
regorafenibPubChemApprovedMET
SelumetinibPubChemApprovedMET
TrametinibPubChemApprovedMET

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot